Global CAR-T Cell Therapy for Pediatric Cancers Market - 2025-2033
Global CAR-T Cell Therapy for Pediatric Cancers Market Size - Industry Trends & Outlook
The global CAR-T cell therapy for pediatric cancers market size reached US$ 2.24 Billion in 2024 and is expected to reach US$ 18.78 Billion by 2033, growing at a CAGR of 26.8% during the forecast period 2025-2033.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells to fight cancer by genetically engineering them in a laboratory. CAR-T cell therapy is an incredibly promising emerging treatment for cancer patients and is increasingly being preferred over chemotherapy, surgery, and radiation. It is increasingly used to treat pediatric patients with B-cell acute lymphoblastic leukemia and in certain types of lymphoma.
The CAR-T cell therapy market for pediatric cancers is witnessing significant growth, fueled by its high therapeutic efficacy in treating relapsed or refractory hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (ALL). Key drivers include rapid technological advancements in CAR-T engineering, strong regulatory support, increased public and private investment, and an expanding pipeline of clinical trials globally.
North America is expected to dominate the market due to its advanced healthcare infrastructure, early adoption, and robust research activity, while Asia-Pacific, especially China, is emerging as a fast-growing region due to increased clinical trial activity and government support.
Global CAR-T Cell Therapy for Pediatric Cancers Market Dynamics: Drivers & Restraints
Rising Research and Developmental Activities in Pediatric Cancer Treatment are Expected to Drive the CAR-T Cell Therapy for Pediatric Cancers Market
Rising research and developmental activities in pediatric cancer treatment are playing a crucial role in driving the CAR-T cell therapy market for pediatric cancers. Increasing investment and focus on next-generation CAR-T therapies, particularly those utilizing advanced engineering techniques and multi-antigen targeting, are significantly expanding treatment possibilities and improving clinical outcomes. These innovations are especially vital for addressing the diverse and complex nature of pediatric cancers.
For instance, on May, 2022, Novartis announced that the U.S. FDA granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This approval marked Kymriah’s third indication, solidifying its status as the only CAR-T therapy approved for both adult and pediatric populations.
Such advancements highlight the increasing momentum in pediatric cancer R&D, with major biopharmaceutical players continually expanding the therapeutic potential of CAR-T treatments. As a result, ongoing innovation in this area is expected to significantly boost market growth and enhance the availability of effective therapies for children battling cancer.
High Treatment Costs of CAR-T Cell Therapy are Expected to Hinder the CAR-T Cell Therapy for Pediatric Cancers Market
Many patients cannot afford CAR-T cell therapy due to its high cost, which frequently exceeds several hundred thousand dollars per patient. This restricts pediatric patients who require potentially life-saving treatments from having access to them. For instance, Kymriah's list price is $475,000, not accounting for costs related to the delivery of care, inpatient hospitalization, toxicity management, or follow-up.
Global CAR-T Cell Therapy for Pediatric Cancers Market Segment Analysis
The global CAR-T cell therapy for pediatric cancers market is segmented based on cancer type, end user, and region.
Treatment:
The acute lymphoblastic leukemia segment is expected to hold 46.7% of the global CAR-T cell therapy for pediatric cancers market
Acute lymphoblastic leukemia (ALL) is expected to dominate the CAR-T cell therapy market for pediatric cancers due to its high prevalence among children and the remarkable success of CAR-T therapies in treating this condition. ALL is the most common type of childhood cancer, accounting for nearly 25% of all pediatric cancer cases. CAR-T therapies, particularly tisagenlecleucel (Kymriah), have demonstrated high remission rates in relapsed or refractory pediatric ALL, significantly improving outcomes where conventional therapies have failed.
For instance, Autolus Therapeutics reported positive updates in September 2024 from its AUTO1/22 study targeting pediatric B-ALL, showing improved safety and sustained efficacy. Given its clinical success and regulatory momentum, ALL remains the leading indication for CAR-T cell therapies in children, reinforcing its dominant position in this rapidly growing market.
High rates of total recovery have been achieved with CAR-T treatments, especially those that target CD19, such as Kymriah, which have demonstrated remarkable success in treating relapsed or refractory B-cell ALL. Because of this achievement, CAR-T is now the suggested method of treatment for this group of patients. Thus, the above factors are expected to hold the segment in the dominant position.
Global CAR-T Cell Therapy for Pediatric Cancers Market Geographical Analysis
North America is expected to hold 42.1% of the global CAR-T cell therapy for pediatric cancers market
North America holds the largest share of the global CAR-T cell therapy market for pediatric cancers and is expected to maintain its dominance in the coming years. This dominance is primarily driven by the region's high incidence of childhood cancers, increasing public awareness of advanced treatment options, and robust investment in research and development.
For instance, according to the American Childhood Cancer Organization, in the United States alone, approximately 15,780 children between birth and 19 years of age are diagnosed with cancer annually, with about 1 in 285 children projected to be diagnosed before turning 20. The rising burden of pediatric cancer has fueled demand for innovative therapies like CAR-T, which offer hope for patients with relapsed or refractory diseases.
Additionally, North America benefits from a well-established healthcare infrastructure, early regulatory approvals, and the presence of leading biotechnology companies, all of which contribute to the accelerated development and adoption of CAR-T therapies in the region. These factors collectively position North America as a key driver of growth in the global pediatric CAR-T cell therapy market.
Asia-Pacific is expected to hold 26.8% of the global CAR-T cell therapy for pediatric cancers market
The Asia-Pacific region is projected to be the fastest-growing market for CAR-T cell therapy in pediatric cancers, driven by a combination of rising cancer incidence, increasing investment in biotechnology, and supportive government South Korea, and India are making significant strides in cancer research and the development of cell-based initiatives.
Countries like China, Japan, therapies. China, in particular, has surpassed the U.S. in the number of CAR-T clinical trials, highlighting its rapid progress and commitment to becoming a global leader in this field.
Government support through funding, regulatory reforms, and public-private partnerships is further fueling innovation and commercialization. As the demand for effective pediatric cancer treatments rises, the Asia-Pacific region is well-positioned to experience substantial growth and emerge as a key player in the global CAR-T cell therapy landscape.
Global CAR-T Cell Therapy for Pediatric Cancers Market Competitive Landscape
The top companies in the CAR-T cell therapy for pediatric cancers market include Novartis AG, and Autolus Therapeutics, Seattle Children’s Hospital, among others.
The global CAR-T cell therapy for pediatric cancers market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
The global CAR-T cell therapy for pediatric cancers market size reached US$ 2.24 Billion in 2024 and is expected to reach US$ 18.78 Billion by 2033, growing at a CAGR of 26.8% during the forecast period 2025-2033.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells to fight cancer by genetically engineering them in a laboratory. CAR-T cell therapy is an incredibly promising emerging treatment for cancer patients and is increasingly being preferred over chemotherapy, surgery, and radiation. It is increasingly used to treat pediatric patients with B-cell acute lymphoblastic leukemia and in certain types of lymphoma.
The CAR-T cell therapy market for pediatric cancers is witnessing significant growth, fueled by its high therapeutic efficacy in treating relapsed or refractory hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (ALL). Key drivers include rapid technological advancements in CAR-T engineering, strong regulatory support, increased public and private investment, and an expanding pipeline of clinical trials globally.
North America is expected to dominate the market due to its advanced healthcare infrastructure, early adoption, and robust research activity, while Asia-Pacific, especially China, is emerging as a fast-growing region due to increased clinical trial activity and government support.
Global CAR-T Cell Therapy for Pediatric Cancers Market Dynamics: Drivers & Restraints
Rising Research and Developmental Activities in Pediatric Cancer Treatment are Expected to Drive the CAR-T Cell Therapy for Pediatric Cancers Market
Rising research and developmental activities in pediatric cancer treatment are playing a crucial role in driving the CAR-T cell therapy market for pediatric cancers. Increasing investment and focus on next-generation CAR-T therapies, particularly those utilizing advanced engineering techniques and multi-antigen targeting, are significantly expanding treatment possibilities and improving clinical outcomes. These innovations are especially vital for addressing the diverse and complex nature of pediatric cancers.
For instance, on May, 2022, Novartis announced that the U.S. FDA granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This approval marked Kymriah’s third indication, solidifying its status as the only CAR-T therapy approved for both adult and pediatric populations.
Such advancements highlight the increasing momentum in pediatric cancer R&D, with major biopharmaceutical players continually expanding the therapeutic potential of CAR-T treatments. As a result, ongoing innovation in this area is expected to significantly boost market growth and enhance the availability of effective therapies for children battling cancer.
High Treatment Costs of CAR-T Cell Therapy are Expected to Hinder the CAR-T Cell Therapy for Pediatric Cancers Market
Many patients cannot afford CAR-T cell therapy due to its high cost, which frequently exceeds several hundred thousand dollars per patient. This restricts pediatric patients who require potentially life-saving treatments from having access to them. For instance, Kymriah's list price is $475,000, not accounting for costs related to the delivery of care, inpatient hospitalization, toxicity management, or follow-up.
Global CAR-T Cell Therapy for Pediatric Cancers Market Segment Analysis
The global CAR-T cell therapy for pediatric cancers market is segmented based on cancer type, end user, and region.
Treatment:
The acute lymphoblastic leukemia segment is expected to hold 46.7% of the global CAR-T cell therapy for pediatric cancers market
Acute lymphoblastic leukemia (ALL) is expected to dominate the CAR-T cell therapy market for pediatric cancers due to its high prevalence among children and the remarkable success of CAR-T therapies in treating this condition. ALL is the most common type of childhood cancer, accounting for nearly 25% of all pediatric cancer cases. CAR-T therapies, particularly tisagenlecleucel (Kymriah), have demonstrated high remission rates in relapsed or refractory pediatric ALL, significantly improving outcomes where conventional therapies have failed.
For instance, Autolus Therapeutics reported positive updates in September 2024 from its AUTO1/22 study targeting pediatric B-ALL, showing improved safety and sustained efficacy. Given its clinical success and regulatory momentum, ALL remains the leading indication for CAR-T cell therapies in children, reinforcing its dominant position in this rapidly growing market.
High rates of total recovery have been achieved with CAR-T treatments, especially those that target CD19, such as Kymriah, which have demonstrated remarkable success in treating relapsed or refractory B-cell ALL. Because of this achievement, CAR-T is now the suggested method of treatment for this group of patients. Thus, the above factors are expected to hold the segment in the dominant position.
Global CAR-T Cell Therapy for Pediatric Cancers Market Geographical Analysis
North America is expected to hold 42.1% of the global CAR-T cell therapy for pediatric cancers market
North America holds the largest share of the global CAR-T cell therapy market for pediatric cancers and is expected to maintain its dominance in the coming years. This dominance is primarily driven by the region's high incidence of childhood cancers, increasing public awareness of advanced treatment options, and robust investment in research and development.
For instance, according to the American Childhood Cancer Organization, in the United States alone, approximately 15,780 children between birth and 19 years of age are diagnosed with cancer annually, with about 1 in 285 children projected to be diagnosed before turning 20. The rising burden of pediatric cancer has fueled demand for innovative therapies like CAR-T, which offer hope for patients with relapsed or refractory diseases.
Additionally, North America benefits from a well-established healthcare infrastructure, early regulatory approvals, and the presence of leading biotechnology companies, all of which contribute to the accelerated development and adoption of CAR-T therapies in the region. These factors collectively position North America as a key driver of growth in the global pediatric CAR-T cell therapy market.
Asia-Pacific is expected to hold 26.8% of the global CAR-T cell therapy for pediatric cancers market
The Asia-Pacific region is projected to be the fastest-growing market for CAR-T cell therapy in pediatric cancers, driven by a combination of rising cancer incidence, increasing investment in biotechnology, and supportive government South Korea, and India are making significant strides in cancer research and the development of cell-based initiatives.
Countries like China, Japan, therapies. China, in particular, has surpassed the U.S. in the number of CAR-T clinical trials, highlighting its rapid progress and commitment to becoming a global leader in this field.
Government support through funding, regulatory reforms, and public-private partnerships is further fueling innovation and commercialization. As the demand for effective pediatric cancer treatments rises, the Asia-Pacific region is well-positioned to experience substantial growth and emerge as a key player in the global CAR-T cell therapy landscape.
Global CAR-T Cell Therapy for Pediatric Cancers Market Competitive Landscape
The top companies in the CAR-T cell therapy for pediatric cancers market include Novartis AG, and Autolus Therapeutics, Seattle Children’s Hospital, among others.
The global CAR-T cell therapy for pediatric cancers market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by End-User
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Research and Developmental Activities in Pediatric Cancer Treatment
3.1.1.2. Increasing Pediatric Cancers
3.1.2. Restraints
3.1.2.1. High Treatment Costs of CAR-T Cell Therapy
3.1.2.2. Complexities in Manufacturing
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Combination Therapies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET CANCER TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Acute Lymphoblastic Leukemia (ALL)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Multiple Myeloma
5.4. Non-Hodgkin Lymphoma
5.5. Others
6. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET END-USER OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
6.1.2. Market Attractiveness Index, By End-User
6.2. Hospitals*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cancer Centers
6.4. Research Institutes
6.5. Others
7. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Key Players
9.1. Novartis AG*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Autolus Therapeutics
9.3. Seattle Children’s Hospital
9.4. Immugenia Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Cancer Type
2.4. Snippet by End-User
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Research and Developmental Activities in Pediatric Cancer Treatment
3.1.1.2. Increasing Pediatric Cancers
3.1.2. Restraints
3.1.2.1. High Treatment Costs of CAR-T Cell Therapy
3.1.2.2. Complexities in Manufacturing
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Combination Therapies
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET CANCER TYPE OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
5.1.2. Market Attractiveness Index, By Cancer Type
5.2. Acute Lymphoblastic Leukemia (ALL)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Multiple Myeloma
5.4. Non-Hodgkin Lymphoma
5.5. Others
6. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET END-USER OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
6.1.2. Market Attractiveness Index, By End-User
6.2. Hospitals*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cancer Centers
6.4. Research Institutes
6.5. Others
7. CAR-T CELL THERAPY FOR PEDIATRIC CANCERS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. UK
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. Asia-Pacific
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. China
7.4.5.2. India
7.4.5.3. Japan
7.4.5.4. South Korea
7.4.5.5. Rest of Asia-Pacific
7.5. South America
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. Brazil
7.5.5.2. Argentina
7.5.5.3. Rest of South America
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
Key Players
9.1. Novartis AG*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Autolus Therapeutics
9.3. Seattle Children’s Hospital
9.4. Immugenia Inc.
LIST NOT EXHAUSTIVE
10. ASSUMPTION AND RESEARCH METHODOLOGY
10.1. Data Collection Methods
10.2. Data Triangulation
10.3. Forecasting Techniques
10.4. Data Verification and Validation
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
LIST OF TABLES
Table 1 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 3 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 4 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)
Table 5 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 6 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 7 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 8 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 9 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2022-2033 (US$ Million)
Table 10 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 11 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 12 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 13 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 14 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 15 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 16 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 17 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 18 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 19 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 20 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 21 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 22 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 23 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 24 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Novartis AG: Overview
Table 26 Novartis AG: Product Portfolio
Table 27 Novartis AG: Key Developments
Table 28 Autolus Therapeutics: Overview
Table 29 Autolus Therapeutics: Product Portfolio
Table 30 Autolus Therapeutics: Key Developments
Table 31 Seattle Children’s Hospital: Overview
Table 32 Seattle Children’s Hospital: Product Portfolio
Table 33 Seattle Children’s Hospital: Key Developments
Table 34 Immugenia Inc.: Overview
Table 35 Immugenia Inc.: Product Portfolio
Table 36 Immugenia Inc.: Key Developments
Table 1 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 3 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 4 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)
Table 5 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 6 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2025, 2029 & 2033 (US$ Million)
Table 7 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 8 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 9 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, By Region, 2022-2033 (US$ Million)
Table 10 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 11 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 12 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 13 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 14 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 15 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 16 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 17 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 18 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 19 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 20 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 21 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 22 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By Cancer Type, 2022-2033 (US$ Million)
Table 23 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By End-User, 2022-2033 (US$ Million)
Table 24 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Novartis AG: Overview
Table 26 Novartis AG: Product Portfolio
Table 27 Novartis AG: Key Developments
Table 28 Autolus Therapeutics: Overview
Table 29 Autolus Therapeutics: Product Portfolio
Table 30 Autolus Therapeutics: Key Developments
Table 31 Seattle Children’s Hospital: Overview
Table 32 Seattle Children’s Hospital: Product Portfolio
Table 33 Seattle Children’s Hospital: Key Developments
Table 34 Immugenia Inc.: Overview
Table 35 Immugenia Inc.: Product Portfolio
Table 36 Immugenia Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 2 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 4 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 6 Acute Lymphoblastic Leukemia (ALL) CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 7 Multiple Myeloma CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 8 Non-Hodgkin Lymphoma CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 9 Others CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 10 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 11 Hospitals End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 12 Cancer Centers End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 13 Research Institutes End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 14 Others End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 15 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 16 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 17 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 18 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 19 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 20 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 21 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 22 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 23 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 24 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 25 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 26 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 27 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 28 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 29 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 30 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 31 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 32 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 33 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 34 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Novartis AG: Financials
Figure 36 Autolus Therapeutics: Financials
Figure 37 Seattle Children’s Hospital: Financials
Figure 38 Immugenia Inc.: Financials
Figure 1 Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 2 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 4 Global CAR-T Cell Therapy for Pediatric Cancers Market Share, By Region, 2024 & 2033 (%)
Figure 5 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 6 Acute Lymphoblastic Leukemia (ALL) CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 7 Multiple Myeloma CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 8 Non-Hodgkin Lymphoma CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 9 Others CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 10 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 11 Hospitals End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 12 Cancer Centers End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 13 Research Institutes End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 14 Others End-User in Global CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 15 Global CAR-T Cell Therapy for Pediatric Cancers Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 16 North America CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 17 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 18 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 19 North America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 20 South America CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 21 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 22 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 23 South America CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 24 Europe CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 25 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 26 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 27 Europe CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 28 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 29 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 30 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 31 Asia-Pacific CAR-T Cell Therapy for Pediatric Cancers Market Share, By Country, 2024 & 2033 (%)
Figure 32 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Value, 2022-2033 (US$ Million)
Figure 33 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 34 Middle East and Africa CAR-T Cell Therapy for Pediatric Cancers Market Share, By End-User, 2024 & 2033 (%)
Figure 35 Novartis AG: Financials
Figure 36 Autolus Therapeutics: Financials
Figure 37 Seattle Children’s Hospital: Financials
Figure 38 Immugenia Inc.: Financials
